The Government’s production-linked incentive (PLI) schemes for key raw materials such as bulk drugs and formulations, with a total incentive outlay of Rs 210 billion will help the country become Aatmanirbhar, ratings agency ICRA said.
As per a note by the agency, PLI scheme will reduce import dependence and boost domestic production of high-value products; and increase the value addition in exports.
High value-added pharmaceutical products are generally R&D intensive and difficult to manufacture and these include products such as complex generics, patented products, and biologics among others.
Further, the GoI has also announced the promotion of the bulk drug parks scheme with a financial outlay of Rs 30 billion for three select states, which will provide infrastructure assistance to the active pharmaceutical ingredient (API) players.
